Importer of Controlled Substances Application: Lipomed, 40687 [2020-14605]
Download as PDF
<![CDATA[
40687
Federal Register / Vol. 85, No. 130 / Tuesday, July 7, 2020 / Notices
products, which defines the scope of the
investigation, is ‘‘drill bits for drilling
frack plugs to complete a well’’;
(3) For the purpose of the
investigation so instituted, the following
are hereby named as parties upon which
this notice of investigation shall be
served:
(a) The complainant is: Varel
International Industries, LLC, 1625 West
Crosby Rd., Suite 124, Carrollton, Texas
75006.
(b) The respondents are the following
entities alleged to be in violation of
section 337, and are the parties upon
which the complaint is to be served:
Kingdream Public Ltd. Co., No. 80
Miaoshan Rd., Wuhan City, Hubei
China Hubei 430223 CN.
Taurex Drill Bits, LLC, 2651 Venture
Drive, Norman, OK 73069.
(4) For the investigation so instituted,
the Chief Administrative Law Judge,
U.S. International Trade Commission,
shall designate the presiding
Administrative Law Judge.
The office of Unfair Import
Investigations will not be named as a
party to this investigation.
Responses to the complaint and the
notice of investigation must be
submitted by the named respondents in
accordance with section 210.13 of the
Commission’s Rules of Practice and
Procedure, 19 CFR 210.13. Pursuant to
19 CFR 201.16(e) and 210.13(a), as
amended in 85 FR 15798 (March 19,
2020), such responses will be
considered by the Commission if
received not later than 20 days after the
date of service by the complainant of the
complaint and the notice of
investigation. Extensions of time for
submitting responses to the complaint
and the notice of investigation will not
be granted unless good cause therefor is
shown.
Failure of a respondent to file a timely
response to each allegation in the
complaint and in this notice may be
deemed to constitute a waiver of the
right to appear and contest the
allegations of the complaint and this
notice, and to authorize the
administrative law judge and the
Commission, without further notice to
the respondent, to find the facts to be as
alleged in the complaint and this notice
and to enter an initial determination
and a final determination containing
such findings, and may result in the
issuance of an exclusion order or a cease
and desist order or both directed against
the respondent.
By order of the Commission.
Issued: July 1, 2020.
Lisa Barton,
Secretary to the Commission.
[FR Doc. 2020–14573 Filed 7–6–20; 8:45 am]
BILLING CODE 7020–02–P
Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for a hearing must
be sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152. All request for a hearing
should also be sent to: (1) Drug
Enforcement Administration, Attn:
Hearing Clerk/OALJ, 8701 Morrissette
Drive, Springfield, Virginia 22152; and
(2) Drug Enforcement Administration,
Attn: DEA Federal Register
Representative/DPW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
ADDRESSES:
In
accordance with 21 CFR 1301.34(a), this
is notice that on June 4, 2020, Lipomed,
150 Cambridgepark Drive, Suite 705,
Cambridge, Massachusetts 02140,
applied to be registered as an importer
of the following basic class(es) of
controlled substances:
SUPPLEMENTARY INFORMATION:
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–672]
Importer of Controlled Substances
Application: Lipomed
ACTION:
Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before August 6, 2020. Such persons
may also file a written request for a
hearing on the application on or before
August 6, 2020.
DATES:
Notice of application.
Controlled substance
Drug code
jbell on DSKJLSW7X2PROD with NOTICES
Ethyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido) 3,3-dimethylbutanoate) ...................................................
N-(Adamantan-1-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboximide) .......................................................................
1-(5-Fluoropentyl)-1H-indazole-3-carboxamide .......................................................................................................
4-methyl-alpha-ethylaminopentiophenone (4-MEAP) ..............................................................................................
N-ethylhexedrone .....................................................................................................................................................
4-chloro-alpha-pyrrolidinovalerophenone (4-chloro-a-PVP) ....................................................................................
a-PHP, alpha-Pyrrolidinohexanophenone ...............................................................................................................
PV8, alpha-Pyrrolidinoheptaphenone ......................................................................................................................
Norfentanyl ...............................................................................................................................................................
The company plans to import the
above controlled substances as
analytical reference standards for
distribution to its customers for research
and analytical purposes. Placement of
these drug codes onto the company’s
registration does not translate into
automatic approval of subsequent
permit applications to import controlled
substances. Approval of permit
applications will occur only when the
registrant’s business activity is
consistent with what is authorized in 21
U.S.C. 952(a)(2). Authorization will not
VerDate Sep<11>2014
16:59 Jul 06, 2020
Jkt 250001
extend to the import of Food and Drug
Administration (FDA)-approved or nonapproved finished dosage forms for
commercial sale.
William T. McDermott,
Assistant Administrator.
[FR Doc. 2020–14605 Filed 7–6–20; 8:45 am]
BILLING CODE P
PO 00000
Frm 00068
Fmt 4703
Sfmt 4703
Schedule
7036
7047
7083
7245
7246
7443
7544
7548
8366
I
I
I
I
I
I
I
I
I
DEPARTMENT OF JUSTICE
Notice of Lodging of Proposed
Consent Decree Under the Resource
Conservation and Recovery Act
On June 30, 2020, the Department of
Justice lodged a proposed Consent
Decree with the United States District
Court for the Southern District of New
York in a lawsuit entitled United States
v. Chestnut Petroleum Distributors, Inc.,
et al., Civil Action No. 19 Civ. 3904
(PHM) (JCM).
E:\FR\FM\07JYN1.SGM
07JYN1
]]>Agencies
[Federal Register Volume 85, Number 130 (Tuesday, July 7, 2020)]
[Notices]
[Page 40687]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-14605]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-672]
Importer of Controlled Substances Application: Lipomed
ACTION: Notice of application.
-----------------------------------------------------------------------
DATES: Registered bulk manufacturers of the affected basic class(es),
and applicants therefore, may file written comments on or objections to
the issuance of the proposed registration on or before August 6, 2020.
Such persons may also file a written request for a hearing on the
application on or before August 6, 2020.
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/DPW,
8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a
hearing must be sent to: Drug Enforcement Administration, Attn:
Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All
request for a hearing should also be sent to: (1) Drug Enforcement
Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive,
Springfield, Virginia 22152; and (2) Drug Enforcement Administration,
Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive,
Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this
is notice that on June 4, 2020, Lipomed, 150 Cambridgepark Drive, Suite
705, Cambridge, Massachusetts 02140, applied to be registered as an
importer of the following basic class(es) of controlled substances:
------------------------------------------------------------------------
Controlled substance Drug code Schedule
------------------------------------------------------------------------
Ethyl 2-(1-(5-fluoropentyl)-1H-indazole- 7036 I
3-carboxamido) 3,3-dimethylbutanoate)..
N-(Adamantan-1-yl)-1-(4-fluorobenzyl)-1H- 7047 I
indazole-3-carboximide)................
1-(5-Fluoropentyl)-1H-indazole-3- 7083 I
carboxamide............................
4-methyl-alpha-ethylaminopentiophenone 7245 I
(4-MEAP)...............................
N-ethylhexedrone........................ 7246 I
4-chloro-alpha-pyrrolidinovalerophenone 7443 I
(4-chloro-a-PVP).......................
[alpha]-PHP, alpha- 7544 I
Pyrrolidinohexanophenone...............
PV8, alpha-Pyrrolidinoheptaphenone...... 7548 I
Norfentanyl............................. 8366 I
------------------------------------------------------------------------
The company plans to import the above controlled substances as
analytical reference standards for distribution to its customers for
research and analytical purposes. Placement of these drug codes onto
the company's registration does not translate into automatic approval
of subsequent permit applications to import controlled substances.
Approval of permit applications will occur only when the registrant's
business activity is consistent with what is authorized in 21 U.S.C.
952(a)(2). Authorization will not extend to the import of Food and Drug
Administration (FDA)-approved or non-approved finished dosage forms for
commercial sale.
William T. McDermott,
Assistant Administrator.
[FR Doc. 2020-14605 Filed 7-6-20; 8:45 am]
BILLING CODE P
